Why do researchers want well-being to count as a clinical-trial endpoint, and how could this change psychedelic research? 

TLDR:

•A 2026 npj Mental Health Research Perspective makes a proposal.

•It says well-being may be a co-primary endpoint.

•Trials should not track only symptom drops.

•Patients often care about meaning and connection.

•They also care about function, energy, and satisfaction.

•Symptom scales may miss some of these areas.

•Safety checks and symptom tracking still matter.

•The proposal calls for valid tools and safeguards.

•Psychedelic trials are a useful example.

•Reported changes may include meaning and connection.

Researchers are asking a simple question. Should success mean only fewer symptoms? Or should it also mean better living? A 2026 Perspective argues for adding well-being. In some trials, it could be a co-primary outcome. (1)

This idea could affect psychedelic-therapy studies. It is about measurement, not a new treatment result. It also does not change treatment rules. Many people do not define recovery by symptoms alone. They may talk about work, trust, purpose, and connection. Those areas can matter deeply. Researchers need clear tools to measure them.

What is a clinical-trial endpoint?

A clinical-trial endpoint is a planned outcome used to judge benefit. Mental health trials often use symptom change as an endpoint. These symptoms can include mood, anxiety, sleep, and intrusive thoughts.

Endpoints are chosen before a trial starts. They help researchers test a clear question. For depression, a symptom scale may track low mood. For PTSD, a scale may track intrusive memories. These tools can show whether core symptoms changed. They can also help spot worsening. 

The 2026 Perspective says these scales may miss valued outcomes. Patients often care about daily roles. They care about relationships and positive emotion. They may want purpose and life quality too. (1) These are not side issues for many people. They can be part of feeling well.

A primary endpoint is a main tested outcome. A co-primary endpoint means more than one main outcome matters. The authors do not say well-being should replace symptoms. They ask whether it can stand beside symptoms. That would only fit some trials. It would also need a valid measure. (1)

Why do researchers want to measure well-being as well as symptoms?

They want a fuller view of whether treatment helps people. Patients often value meaning, connection, function, vitality, and satisfaction. Standard symptom scales may not capture these areas. (1)

This issue is clear in many therapy conversations. A person may say panic attacks are less frequent. Yet they may still feel cut off from others. Another person may sleep better. Yet they may still feel life has no meaning. A symptom score can improve while life still feels thin. 

The reverse can also happen. A person may still have symptoms. Yet they may feel more connected and able. They may return to work. They may repair a bond. They may feel more hope. Researchers want ways to measure these changes fairly.

This is relevant to psychedelic studies. Some participants report shifts in meaning. Others report more connectedness or self-compassion. Some describe behavior changes after the session. These shifts may come before symptom scores move. Some may last after symptom change levels off. (1) 

Still, a meaningful experience is not proof of benefit. People can feel moved for many reasons. Trials must compare groups with clear measures. They must use tools that are valid and reliable. For more on emotional well-being, see The Compassion Connection: How Psychedelic Therapy Enhances Emotional Well-being and Mindfulness. The goal is not to promise a feeling. It is to value outcomes patients name.

How would researchers measure well-being fairly?

The authors propose a shared tool built through a Delphi process. A Delphi process gathers structured input over several rounds. It aims to reach agreement on what to measure.

The input would come from experts and stakeholders. Stakeholders can include patients and care partners. They can also include clinicians and researchers. The goal is not one person’s favorite scale. The goal is a fair, agreed-upon tool. 

The tool must measure more than a pleasant mood. A good day is not the same as lasting well-being. The article treats well-being as broad. It can include positive feeling and life satisfaction. It can also include psychological function. (1)

A credible tool must be clear to users. It must be stable enough over time. It must also detect real change. If a tool is too vague, it can mislead. If it is too narrow, it can miss recovery. If it is too easy to sway, it can overstate benefit. 

This plan fits with the FDA’s patient-focused work. The FDA has discussed patient experience data in drug development. It has also discussed clinical outcome assessments. (2) That does not make every patient-reported tool trial-ready. The measure must fit the study question. It must be built and tested with care.

Could a treatment pass if symptoms get worse but well-being improves?

No. The authors call for safeguards. A treatment should not pass if symptoms worsen. Well-being should complement symptoms and safety, not override them. (1)

This point is vital. A person can report meaning after a hard event. That does not mean the event was safe. A person can feel inspired for a short time. That does not prove lasting benefit. A trial must still track harm and function. 

In psychedelic research, this matters even more. The experiences can be intense. Some may feel deeply meaningful. Clinicians and researchers still must track distress. They must also track adverse events and symptom worsening. Long-term outcomes also matter.

The FDA’s 2026 guidance stresses careful trial design. Psychedelic-drug studies can have blinding problems. They can also involve unusual subjective effects. Strong support and safety plans may be needed. (3) 

The National Center for Complementary and Integrative Health also urges caution. Psilocybin research is active. Risks can vary by person and setting. Differences between people matter too. (4) A fuller view of recovery should raise standards. It should not lower them.

If you are naming what “better” means, therapy can help. Positive psychology can explore strengths, values, and meaning. Individual therapy makes room for symptoms and life issues.

What is the bottom line on well-being in psychedelic trials?

The call to measure well-being aims to match patient values. It does not say symptoms no longer matter. It does not prove psychedelic therapies help everyone. It asks for better tools and questions. (1)

This proposal may make trials more human. It may help researchers see more than symptom drops. It may also help compare treatments more fairly. But well-being must be measured with care. Safety and disorder-specific symptoms must stay central. 

You may feel symptom checklists miss your real pain. Maybe the loss is meaning. Maybe it is strained ties. Maybe it is not feeling like yourself. Those concerns matter. A fuller view of recovery should include them. It should still rest on evidence and safety.

Jeff Jones, LPC, offers positive psychology-informed counseling. He also offers psychedelic integration support. He helps people explore meaning and growth with care. If you want to discuss a fuller view of “feeling better,” schedule a free consultation with Jeff Jones, LPC. 

About the Author: This article was written by Jeff Jones, a Licensed Professional Counselor (LPC) in Texas in practice since 1999. He is a 2024 graduate of the CIIS Center for Psychedelic Therapies and Research program. With a compassionate and evidence-based approach, he helps clients navigate life's challenges and find a path toward healing. 

Disclaimer: The information in this article, including discussions of psychedelic-assisted psychotherapy, is for informational purposes only. Psychedelic-assisted psychotherapy has not been approved by all regulatory agencies in the United States, and its safety and efficacy are still being established. This content is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. 

References

1.Marseille, E., Kettner, H., Sgambati, T. J., Kahn, J. G., Bertozzi, S., Lucas, W., Carhart-Harris, R., Keltner, D., & Raison, C. (2026). Well-being as a primary endpoint in clinical trials: A call for consensus. npj Mental Health Research, 5, 39. https://doi.org/10.1038/s44184-026-00234-1

2.U.S. Food and Drug Administration. (2023, April ). Patient-focused drug development: Incorporating clinical outcome assessments into endpoints for regulatory decision-making. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory

3.U.S. Food and Drug Administration. (2026, July ). Psychedelic drugs: Considerations for clinical investigations. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations

4.National Center for Complementary and Integrative Health. (n.d. ). Psilocybin for mental health and addiction: What you need to know. National Institutes of Health. https://www.nccih.nih.gov/health/psilocybin-for-mental-health-and-addiction-what-you-need-to-know